Anticholinergics in asthma: are we utilizing asthma therapies effectively?
Department of Pediatric Pulmonology and Allergy, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
Data have shown that asthma is the most prevalent chronic respiratory disease, affecting 358 million people worldwide in 2015.1 While data show that the age-standardized asthma-related death rate decreased by 58.8% from 1990–2015,1 asthma still represents a significant burden in terms of morbidity.2 As such, there is an important role for utilizing add-on therapy options. The focus of this review series is on the use of long-acting anticholinergic add-on therapy to reduce asthma morbidity.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]